IQVIA IQV · NYSE
$265.83 -0.40% (-$1.07)
Summary
55 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 15 USD is left as free cash.
- It beat profit estimates 8 times in the last 8 quarters.
What to watch
- The share price is above the Bulios Fair Price.
- Repaying its net debt would take 4.1 years of operating profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 32.0 USD for 1 USD of yearly profit. Over the last five years it was 35.9 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 7.5% a year over 5 years. Over the last 3 years it grew by 4.2% a year. For the next fiscal year analysts expect revenue to grow by 6.7%. Earnings per share grew by 11% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 74 USD
- Sales and administration 13 USD
- Taxes and other 5.5 USD
- Net profit 8.1 USD
Net profit, industry median (Medical - Diagnostics & Research) 8.8 USD
Out of every 100 USD of revenue, 8.1 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 6.2 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 37
- Hold 7
- Sell 1
Today's price within the analysts' price targets
The average target of $282.8 is 6.4% above today's price. 82% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Research And Development Solutions 55%
- Technology And Analytics Solutions 41%
- Contract Sales And Medical Solutions 4.8%
By region
- Americas 47%
- EMEA 32%
- Asia Pacific 21%
Research And Development Solutions brings in 55% of revenue. Technology And Analytics Solutions grew fastest, by 4.6% a year.
Segments in detail